COVID-19 Sample Collection Kits Market Report, Upcoming Trends, Demand, Analysis and Forecast 2021 to 2026
iCrowd Newswire
03 May 2021, 20:26 GMT+10
According to IMARC Group latest report titled COVID-19 Sample Collection Kits Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 , the market is currently witnessing strong growth. The
Market Trends:
COVID-19 sample collection kits are the in-vitro diagnostic medical equipment utilized for collecting biological specimens to detect the SARS-CoV-2 virus. It is a vital step in the effective diagnosis of an active infection of the novel coronavirus in the body. With the proliferating number of diagnostic centers and labs expanding their testing capabilities, the demand for COVID-19 collection sample kits is escalating worldwide.
ASM joined partners in submitting the following request to Congress.
Dear Chairman Leahy, Vice Chairman Shelby, Chair Murray and Ranking Member Blunt
cc: Chair DeLauro, Ranking Member Granger and Ranking Member Cole:
We, the undersigned organizations, respectfully request that you provide $60 million for the Advanced Molecular Detection (AMD) program at the Centers for Disease Control and Prevention (CDC) in the Fiscal Year (FY) 2022 Labor, Health and Human Services, Education and Related Agencies bill. The AMD program uses next generation sequencing (NGS) to bring the concept of precision medicine to bear for “precision public health.”
AMD gives us new tools to detect disease faster, identify outbreaks sooner, and protect people from emerging and evolving disease threats. It informs vaccine development, helps identify and track antimicrobial resistance and foodborne illness, and informs the development of diagnostics for new, existing and emerging diseases. AMD has played a
Press release content from Business Wire. The AP news staff was not involved in its creation.
Labcorp Announces 2021 First Quarter Results
April 29, 2021 GMT
BURLINGTON, N.C. (BUSINESS WIRE) Apr 29, 2021
Labcorp (NYSE: LH), a leading life sciences company, today announced results for the first quarter ended March 31, 2021 and raised 2021 guidance.
“We delivered very strong results in the first quarter driven by revenue growth across both our Diagnostics and Drug Development businesses,” said Adam H. Schechter, chairman and CEO, Labcorp. “Overall revenue in our base business grew 14.6% as people continued to return to their pre-pandemic healthcare routines and our biopharmaceutical clients resumed their important research and development. Our drug development pipeline remained robust, with a book-to-bill of 1.47 on a trailing twelve-month basis driven by strong demand across major therapeutic areas.”